CTLA4 and melanoma: Furthermore, in another study analyzing flow cytometry data with supervised clustering from PBMCs in 90 advanced melanoma patients treated with anti-PD-1 and anti-CTLA-4 combinations, an increase in circulating CD4+ Tem cells correlated positively with longer PFS [30].